{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:22:20Z","timestamp":1783786940511,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ygyno.2019.10.029","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T09:04:32Z","timestamp":1573808672000},"page":"32-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer"],"prefix":"10.1016","volume":"156","author":[{"given":"Sarah E.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjiao","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Elvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin K.","family":"Zorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.10.029_bib1","series-title":"SEER Cancer Statistics Review","year":"1975"},{"issue":"9951","key":"10.1016\/j.ygyno.2019.10.029_bib2","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.10.029_bib3","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1200\/JCO.2005.02.194","article-title":"Targeting signal transduction pathways in colorectal cancer \u2013 more than skin deep","volume":"23","author":"Cohen","year":"2005","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.10.029_bib4","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","article-title":"AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth","volume":"34","author":"Altomare","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2019.10.029_bib5","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1517\/13543780903321508","article-title":"The rationale for mTOR inhibition in epithelial ovarian cancer","volume":"18","author":"Trinh","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ygyno.2019.10.029_bib6","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.2174\/092986710794182999","article-title":"PI3K\/AKT\/mTOR inhibitors in ovarian cancer","volume":"36","author":"Mazzoletti","year":"2010","journal-title":"Curr. Med. Chem."},{"issue":"10","key":"10.1016\/j.ygyno.2019.10.029_bib7","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.18632\/oncotarget.1799","article-title":"Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K\/AKT\/mTOR pathway","volume":"5","author":"Wheler","year":"2014","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ygyno.2019.10.029_bib8","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s10637-015-0288-5","article-title":"A\u00a0pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-\u03b2, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort","volume":"33","author":"Werner","year":"2015","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ygyno.2019.10.029_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2011.06.022","article-title":"Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study","volume":"1","author":"Behbakht","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.10.029_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ygyno.2017.04.020","article-title":"Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers","volume":"146","author":"Colon-Otero","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.10.029_bib11","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1053\/beog.2000.0134","article-title":"Angiogenesis in ovarian cancer","volume":"14","author":"Brown","year":"2000","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.ygyno.2019.10.029_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10456-005-9001-1","article-title":"Angiogenesis in normal and neoplastic ovaries","volume":"8","author":"Ramakrishnan","year":"2005","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ygyno.2019.10.029_bib13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2010.11.035","article-title":"Overview of anti-angiogenic agents in development for ovarian cancer","volume":"121","author":"Burger","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.10.029_bib14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ygyno.2004.05.056","article-title":"VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma","volume":"94","author":"Chen","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.10.029_bib15","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.10.029_bib16","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.10.029_bib17","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.10.029_bib18","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.10.029_bib19","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.10.029_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2019.10.029_bib21","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.10.029_bib22","series-title":"Scientific Plenary #3 Presented at the 2015 Annual Meeting for Women's Cancers","author":"Coleman","year":"2015"},{"issue":"suppl","key":"10.1016\/j.ygyno.2019.10.029_bib23","article-title":"Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors","volume":"24","author":"Zafar","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2019.10.029_bib24","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2011-0078","article-title":"A\u00a0phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer","volume":"16","author":"Altomare","year":"2011","journal-title":"The Oncologist"},{"issue":"2","key":"10.1016\/j.ygyno.2019.10.029_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.clgc.2012.12.002","article-title":"A\u00a0phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma","volume":"11","author":"Harshman","year":"2013","journal-title":"Clin. Genitourin. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2019.10.029_bib26","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ygyno.2019.10.029_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"issue":"3","key":"10.1016\/j.ygyno.2019.10.029_bib28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ygyno.2017.09.031","article-title":"Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type","volume":"147","author":"Lin","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.10.029_bib29","series-title":"American Association for Cancer Research Annual Meeting","article-title":"A\u00a0validated diagnostic assay for identifying ovarian cancer patients with deleterious BRCA mutations and high genomic loss of heterozygosity (LOH). Poster","author":"Sun","year":"2018"},{"issue":"2","key":"10.1016\/j.ygyno.2019.10.029_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ygyno.2018.08.027","article-title":"A\u00a0randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or primary peritoneal cancer: an NRG oncology\/gynecologic oncology group study","volume":"151","author":"Tew","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.10.029_bib31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gore.2017.02.007","article-title":"Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options","volume":"20","author":"Elvin","year":"2017","journal-title":"Gynecol. Oncol. Rep."},{"issue":"16","key":"10.1016\/j.ygyno.2019.10.029_bib32","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-17-3060","article-title":"Integrative kinome profiling identifies mTORC1\/2 inhibition as treatment strategy in ovarian clear cell carcinoma","volume":"24","author":"Caumanns","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.10.029_bib33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40661-015-0013-2","article-title":"Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease","volume":"2","author":"Castro","year":"2015","journal-title":"Gynecol. Oncol. Res. Pract."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819316166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819316166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:49:10Z","timestamp":1758772150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819316166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0090825819316166"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.10.029","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}